Literature DB >> 11821583

Treatment of Helicobacter pylori infection.

J Wu1, J Sung.   

Abstract

The availability of clinic-based diagnostic tests means that screening for and the eradication of Helicobacter pylori can be done by primary care physicians. However, confusion still exists regarding indication and treatment regimens. It is universally accepted that patients with Helicobacter pylori infection and peptic ulcer disease require eradication therapy. But the benefits of Helicobacter pylori eradication in gastro-oesophageal reflux disease, non-steroidal anti-inflammatory drug-related peptic ulceration, and non-ulcer dyspepsia remain unclear. There is no evidence that the elimination of Helicobacter pylori is beneficial for asymptomatic patients or in preventing gastric cancer. One-week triple therapy with a proton pump inhibitor or ranitidine bismuth citrate in combination with clarithromycin/metronidazole and amoxycillin is the recommended first-line treatment for Helicobacter pylori infection. Problems with patient compliance and the development of antibiotic resistance are the two most important factors to consider when choosing the treatment regimen. The optimal retreatment therapy for treatment failure is still unknown, and quadruple therapy is best reserved for these cases.

Entities:  

Year:  1999        PMID: 11821583

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  2 in total

1.  Standard triple versus levofloxacin based regimen for eradication of Helicobacter pylori.

Authors:  Raj Gopal; Thirthar Palanivelu Elamurugan; Vikram Kate; Sadasivan Jagdish; Debdatta Basu
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-05-06

2.  In Vitro and In Vivo Anti-Helicobacter Activities of Eryngium foetidum (Apiaceae), Bidens pilosa (Asteraceae), and Galinsoga ciliata (Asteraceae) against Helicobacter pylori.

Authors:  Laure Brigitte Kouitcheu Mabeku; Bertrand Eyoum Bille; Eveline Nguepi
Journal:  Biomed Res Int       Date:  2016-08-18       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.